- Home
- MODD vs CELU Comparison
MODD vs CELU Comparison
Compare MODD & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MODD
- CELU
- Stock Information
- Founded
- MODD 1998
- CELU 2016
- Country
- MODD United States
- CELU United States
- Employees
- MODD N/A
- CELU N/A
- Industry
- MODD Industrial Specialties
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- MODD Health Care
- CELU Health Care
- Exchange
- MODD Nasdaq
- CELU Nasdaq
- Market Cap
- MODD 46.3M
- CELU 42.2M
- IPO Year
- MODD N/A
- CELU N/A
- Fundamental
- Price
- MODD $0.71
- CELU $2.96
- Analyst Decision
- MODD
- CELU
- Analyst Count
- MODD 0
- CELU 0
- Target Price
- MODD N/A
- CELU N/A
- AVG Volume (30 Days)
- MODD 132.7K
- CELU 578.5K
- Earning Date
- MODD 08-13-2025
- CELU 05-08-2025
- Dividend Yield
- MODD N/A
- CELU N/A
- EPS Growth
- MODD N/A
- CELU N/A
- EPS
- MODD N/A
- CELU N/A
- Revenue
- MODD N/A
- CELU $54,220,000.00
- Revenue This Year
- MODD N/A
- CELU $23.29
- Revenue Next Year
- MODD N/A
- CELU N/A
- P/E Ratio
- MODD N/A
- CELU N/A
- Revenue Growth
- MODD N/A
- CELU 138.11
- 52 Week Low
- MODD $0.63
- CELU $1.00
- 52 Week High
- MODD $2.65
- CELU $5.22
- Technical
- Relative Strength Index (RSI)
- MODD 45.17
- CELU 58.85
- Support Level
- MODD $0.68
- CELU $2.01
- Resistance Level
- MODD $0.78
- CELU $4.35
- Average True Range (ATR)
- MODD 0.06
- CELU 0.38
- MACD
- MODD 0.01
- CELU 0.10
- Stochastic Oscillator
- MODD 37.93
- CELU 44.62
About MODD Modular Medical Inc.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.